Skip to content

Supplementation in dysmenorrhea

Effects of separate and concurrent supplementation of n-3 fatty acids and rosa damascena extract on primary dysmenorrhea

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201403105670N8
Enrollment
120
Registered
2014-04-12
Start date
2014-03-06
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary dysmenorrhea. Primary dysmenorrhea

Interventions

Intervention 1: Control Group: placeboes of FAsn-3 and rosa damascena extract every day for 2 mounths. Intervention 2: Intervention group 2: oral capsul containing of 800mg rosa damscena extract and p
Placebo
Control Group: placeboes of FAsn-3 and rosa damascena extract every day for 2 mounths
Intervention group 2: oral capsul containing of 800mg rosa damscena extract and placebo of FAsn-3 containing paraffin every day for two mounths.
Intervention group 1: FAsn-3 oral capsule.1 g containing 180 mg EPA &120mg DHA and placebo of rosa damascena extract containing starch every day for two mounths
Intervention group3: FAsn-3 oral capsule,1g containing 180 mg EPA and 120 mg DHA and oral capsule containing 800 mg rosa damascena extract every day for two mounths

Sponsors

Research deputy of Tabriz University of Medical Sience
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:having dysmenorrhea in menstrual cycles in most recent years; women with moderate and severe dysmenorrhea according to VAS and MDS systems; regular menstrual cycles (21-35 day); body mass index in normal range (BMI)=18.5-24.9, Exclusion criteria: being married; history of hypersensivity for fish, seafoods and rosa damascena,; stressful event (loss of one family members, parental separation,… ); regular consumption of nutritional supplements and vitamins, oral contraceptives and other drugs; special diets like weight loss/gain diets; performing any surgery during the study; smoking and alcohol consumption; lack of complianc

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Dysmenorrhea pain severity. Timepoint: befor,1,2 mounth after intervention. Method of measurement: Visual Analog Scale (VAS)- 1-10 score.;Severity of systematic symptoms of dysmenorrhea. Timepoint: befor,1,2 mounth after intervention. Method of measurement: Visual Analoge Scale (VAS)- 1-10 score.;Menstrual duration. Timepoint: before and after of intervention. Method of measurement: Complete of questionnare.;Amount of blood loss. Timepoint: before and after of intervention. Method of measurement: Complete of questionnare.;Appetite. Timepoint: befor,1,2 mounth after intervention. Method of measurement: Visual Analoge Scale (VAS)- 1-100 score.;Calorie and macronutrient intake. Timepoint: before and after of intervention. Method of measurement: Food record for 3 day.

Secondary

MeasureTime frame
Body weight. Timepoint: before and after of intervention. Method of measurement: Measurment of weight by scale (kg).;Waist circumference. Timepoint: before and after of intervention. Method of measurement: meter (cm).

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026